Annual Cash & Cash Equivalents
$1.40 M
+$573.00 K+69.04%
31 December 2022
Summary:
Nymox Pharmaceutical annual cash & cash equivalents is currently $1.40 million, with the most recent change of +$573.00 thousand (+69.04%) on 31 December 2022. During the last 3 years, it has fallen by -$2.21 million (-61.15%).NYMX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$351.00 K
-$1.05 M-74.98%
31 March 2023
Summary:
Nymox Pharmaceutical quarterly cash and cash equivalents is currently $351.00 thousand, with the most recent change of -$1.05 million (-74.98%) on 31 March 2023.NYMX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NYMX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | -61.1% | -88.8% |
| 5 y5 years | -82.3% | -95.1% |
NYMX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | -89.4% | -97.3% |
Nymox Pharmaceutical Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $351.00 K(-75.0%) |
| Dec 2022 | $1.40 M(+69.0%) | $1.40 M(-48.1%) |
| Sept 2022 | - | $2.70 M(-33.6%) |
| June 2022 | - | $4.07 M(+505.7%) |
| Mar 2022 | - | $672.00 K(-19.0%) |
| Dec 2021 | $830.00 K(-77.0%) | $830.00 K(-73.6%) |
| Sept 2021 | - | $3.14 M(-49.3%) |
| June 2021 | - | $6.20 M(+604.7%) |
| Mar 2021 | - | $880.00 K(-75.6%) |
| Dec 2020 | $3.61 M(-31.1%) | $3.61 M(-32.7%) |
| Sept 2020 | - | $5.37 M(+599.5%) |
| June 2020 | - | $767.00 K(-74.5%) |
| Mar 2020 | - | $3.00 M(-42.7%) |
| Dec 2019 | $5.24 M(-34.1%) | $5.24 M(-26.6%) |
| Sept 2019 | - | $7.14 M(-21.5%) |
| June 2019 | - | $9.10 M(-19.5%) |
| Mar 2019 | - | $11.29 M(+42.1%) |
| Dec 2018 | $7.95 M(+833.7%) | $7.95 M(+70.6%) |
| Sept 2018 | - | $4.66 M(-7.6%) |
| June 2018 | - | $5.04 M(+492.9%) |
| Mar 2018 | - | $850.00 K(-0.1%) |
| Dec 2017 | $851.00 K(-57.8%) | $851.00 K(-51.1%) |
| Sept 2017 | - | $1.74 M(+37.5%) |
| June 2017 | - | $1.26 M(-22.5%) |
| Mar 2017 | - | $1.63 M(-19.1%) |
| Dec 2016 | $2.02 M(+439.6%) | $2.02 M(+28.5%) |
| Sept 2016 | - | $1.57 M(+858.5%) |
| June 2016 | - | $163.90 K(-80.3%) |
| Mar 2016 | - | $831.10 K(+122.2%) |
| Dec 2015 | $374.00 K(-40.9%) | $374.00 K(+136.1%) |
| Sept 2015 | - | $158.40 K(-81.8%) |
| June 2015 | - | $872.50 K(+130.7%) |
| Mar 2015 | - | $378.20 K(-40.2%) |
| Dec 2014 | $632.30 K(+114.0%) | $632.30 K(+223.1%) |
| Sept 2014 | - | $195.70 K(+141.0%) |
| June 2014 | - | $81.20 K(-67.4%) |
| Mar 2014 | - | $249.30 K(-15.6%) |
| Dec 2013 | $295.50 K(-71.3%) | $295.50 K(-54.7%) |
| Sept 2013 | - | $652.50 K(-12.0%) |
| June 2013 | - | $741.50 K(-46.1%) |
| Mar 2013 | - | $1.38 M(+33.5%) |
| Dec 2012 | $1.03 M(-82.6%) | $1.03 M(-33.8%) |
| Sept 2012 | - | $1.56 M(-28.9%) |
| June 2012 | - | $2.19 M(-32.4%) |
| Mar 2012 | - | $3.24 M(-45.3%) |
| Dec 2011 | $5.92 M(-55.1%) | $5.92 M(+0.1%) |
| Sept 2011 | - | $5.91 M(-15.7%) |
| June 2011 | - | $7.01 M(-24.9%) |
| Mar 2011 | - | $9.34 M(-29.1%) |
| Dec 2010 | $13.18 M | $13.18 M(+2584.4%) |
| Sept 2010 | - | $490.80 K(+8.7%) |
| June 2010 | - | $451.60 K(-42.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2010 | - | $779.10 K(+16.5%) |
| Dec 2009 | $668.70 K(+142.4%) | $668.70 K(-35.7%) |
| Sept 2009 | - | $1.04 M(+53.1%) |
| June 2009 | - | $679.50 K(+59.4%) |
| Mar 2009 | - | $426.20 K(+54.5%) |
| Dec 2008 | $275.90 K(+1.0%) | $275.90 K(-34.7%) |
| Sept 2008 | - | $422.60 K(+67.7%) |
| June 2008 | - | $252.00 K(-47.7%) |
| Mar 2008 | - | $481.70 K(+76.4%) |
| Dec 2007 | $273.10 K(+16.2%) | $273.10 K(-20.7%) |
| Sept 2007 | - | $344.50 K(-65.0%) |
| June 2007 | - | $984.00 K(+68.6%) |
| Mar 2007 | - | $583.70 K(+148.3%) |
| Dec 2006 | $235.10 K(+55.2%) | $235.10 K(-3.4%) |
| Sept 2006 | - | $243.50 K(+98.8%) |
| June 2006 | - | $122.50 K(-88.2%) |
| Mar 2006 | - | $1.04 M(+587.9%) |
| Dec 2005 | $151.50 K(-71.4%) | $151.50 K(-35.0%) |
| Sept 2005 | - | $233.00 K(+50.8%) |
| June 2005 | - | $154.50 K(-5.5%) |
| Mar 2005 | - | $163.50 K(-69.1%) |
| Dec 2004 | $529.60 K(-12.5%) | $529.60 K(+51.1%) |
| Sept 2004 | - | $350.50 K(-3.8%) |
| June 2004 | - | $364.20 K(-3.7%) |
| Mar 2004 | - | $378.20 K(-37.5%) |
| Dec 2003 | $605.60 K(-8.3%) | $605.60 K(-21.2%) |
| Sept 2003 | - | $768.60 K(+312.1%) |
| June 2003 | - | $186.50 K(-73.4%) |
| Mar 2003 | - | $700.40 K(+6.0%) |
| Dec 2002 | $660.60 K(+35.1%) | $660.60 K(+74.2%) |
| Sept 2002 | - | $379.30 K(-26.3%) |
| June 2002 | - | $514.70 K(-45.4%) |
| Mar 2002 | - | $942.60 K(+92.8%) |
| Dec 2001 | $489.00 K(-13.6%) | $489.00 K(-26.7%) |
| Sept 2001 | - | $667.40 K(+62.9%) |
| June 2001 | - | $409.80 K(-25.5%) |
| Mar 2001 | - | $549.90 K(-2.8%) |
| Dec 2000 | $565.70 K(+25.9%) | $565.70 K(-36.0%) |
| Sept 2000 | - | $883.70 K(-43.0%) |
| June 2000 | - | $1.55 M(-44.8%) |
| Mar 2000 | - | $2.81 M(+524.4%) |
| Dec 1999 | $449.40 K(-9.2%) | $449.40 K(-10.0%) |
| Sept 1999 | - | $499.60 K(-58.2%) |
| June 1999 | - | $1.19 M(-20.4%) |
| Mar 1999 | - | $1.50 M(+203.2%) |
| Dec 1998 | $494.90 K(-70.9%) | $494.90 K(-80.3%) |
| Sept 1998 | - | $2.51 M(-37.4%) |
| June 1998 | - | $4.00 M(+90.7%) |
| Mar 1998 | - | $2.10 M(+23.6%) |
| Dec 1997 | $1.70 M | $1.70 M(-5.6%) |
| Sept 1997 | - | $1.80 M(-41.9%) |
| June 1997 | - | $3.10 M |
FAQ
- What is Nymox Pharmaceutical annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Nymox Pharmaceutical?
What is Nymox Pharmaceutical annual cash & cash equivalents?
The current annual cash & cash equivalents of NYMX is $1.40 M
What is the all time high annual cash & cash equivalents for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high annual cash & cash equivalents is $13.18 M
What is Nymox Pharmaceutical quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NYMX is $351.00 K
What is the all time high quarterly cash and cash equivalents for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high quarterly cash and cash equivalents is $13.18 M